AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01545531 — intervention group
Intervention type: DRUG
Intervention: Iohexol
Description: Iohexol, a non-ionic, low osmolar, X-ray contrast medium (OmnipaqueR) that is safe and non-toxic and used for angiographic and urographic procedures, is eliminated from plasma exclusively by glomerular filtration \[13\]. Study subject will receive 5 ml of iohexol solution (Omnipaque 300, corresponding to 647 mg iohexol per ml or 300 mg iodine per ml) through peripheral IV or central Line infusion over 1-2 minutes followed by 10 ml of saline solution at baseline, day 100 and 1 year after HCT.
Study NCT02007681 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduction of sedentary time by breaking it with low intensity physical activity
Description: One 5-10 minute break per hour during the work day using a software that alert the participant, and perform 6000 steps above the baseline number of steps/day (previously evaluated), by adopting several domain specific strategies, during 7 days.
Study NCT02464592 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transbronchial lung biopsy.
Description: Transbronchial lung biopsy with cryoprobe and with conventional forceps.
Study NCT00791778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Patients in Sorafenib arm will receive 2 Sorafenib tablets (200 mg each) twice a day and in continuous administration.
Study NCT00791778 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in Placebo arm will receive 2 matching placebo tablets twice a day and in continuous administration.
Study NCT02689193 — intervention group
Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sampling (Volume depending on age, minimum 2.0 ml, maximum 10.9 ml extra)
Study NCT01820117 — intervention group
Intervention type: OTHER
Intervention: Neurocognitive Evaluation
Description: The neurocognitive evaluation will include measures of academic achievement, intelligence, sustained attention, memory, processing speed, executive functions, functional behavior, and emotional functioning.
Study NCT01820117 — intervention group
Intervention type: OTHER
Intervention: Quantitative Brain Imaging
Description: Imaging will include raw images to both quantify white matter hyperintensities and hemosiderin deposits, as well as cortical thickness and tissue segmentation. Brain imaging will be repeated on participants who are concurrently enrolled on BRIGHT and MIND protocols at St. Jude and who completed prior brain imaging during the BRIGHT clinic visit. The repeat MRI will be done at their 6 month MIND clinic visit.
Study NCT01820117 — intervention group
Intervention type: OTHER
Intervention: Neurologic Evaluation
Description: Evaluation includes a complete review of neurologic symptoms, and interview and examination by the neurologist, assessment of neurologic symptoms and determination of their impact on day-to-day living, and quantified neurologic examination by the neurologist.
Study NCT01820117 — intervention group
Intervention type: OTHER
Intervention: Health Questionnaire
Description: Participants will be asked to complete an approximately 450-item survey to assess health history and status, social and demographic factors, health behaviors, and psychosocial constructs.
Study NCT01820117 — intervention group
Intervention type: OTHER
Intervention: Vascular Testing
Description: Digital assessment of endothelial function will be studied, and central blood and pulse pressure and carotid-femoral pulse wave velocity will be non-invasively measured.
Study NCT01820117 — intervention group
Intervention type: OTHER
Intervention: Cardiopulmonary Exercise Testing
Description: Study participants will undergo cardiopulmonary exercise testing by treadmill. Those participants whose physical performance does not permit walking safely on the treadmill (extreme deconditioning, lower extremity paralysis, balance disorder, acute lower extremity injury) will perform cardiopulmonary exercise testing on a bicycle or upper extremity ergometer using a comparable testing protocol.
Study NCT01820117 — intervention group
Intervention type: OTHER
Intervention: Echocardiography
Description: A complete 3D as well as 2D echocardiogram with Doppler and M-mode will be performed.
Study NCT01820117 — intervention group
Intervention type: OTHER
Intervention: Pulmonary Function Testing
Description: Pulmonary function testing will include spirometry, lung volume measurements by body plethysmography, and single-breath carbon monoxide-diffusion capacity (DLCO).
Study NCT01820117 — intervention group
Intervention type: PROCEDURE
Intervention: Serum Biomarkers
Description: Blood for serum biomarkers associated with cardiovascular morbidity will be drawn, including high-sensitivity C-reactive protein, serum homocysteine.
Study NCT01820117 — intervention group
Intervention type: OTHER
Intervention: Ophthalmology Examination
Description: Ophthalmology examination will include a review of symptoms, examination, and fundus imaging. The examination will consist of visual acuity testing, refraction testing, retinoscopy, ocular pressure, and examination under mydriasis. Fundus photography will be used to capture an image of the retina for examination of potential hypertensive retinopathy.
Study NCT04522401 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: consultation: Bien vieillir
Description: Patients will benefit from a multidisciplinary assessment including a geriatric assessment standardized by a geriatrician, an evaluation by a dietician, an evaluation by an occupational therapist. They will then be exposed to a personalized plan of care in the form of a recommendation.Then, patients will be followed at home to evaluate the implementation of their personalized care plan at 3 months of their assessment day, then at 6 and 9 months.
Study NCT02813850 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oxygen therapy
Description: Oxygen therapy early in the night (2L/min) during 4hours per days
Study NCT02475096 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered CBT
Description: The treatment is based on an internet-delivered CBT-treatment for adults with IBS and on the adapted version for adolescents with functional gastrointestinal disorders. The protocol has been tested in an open face-to-face CBT study of children aged 8-12 years (n=20) with promising results.~Main component in the treatment is exposure for symptoms. The purpose of the treatment is to reduce fearful and anxious responses to symptoms and lessen avoidance of symptoms in the child, and to teach the parents how parental behavior can influence symptoms in children as well as how to support exposure. Detailed behaviour analysis is made for each individual and instruction is given on how to gradually expose to symptoms to lessen fear for symptoms and widen the behavioral repertoire.
Study NCT05440526 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Herbst Group
Description: Herbst Group:~1. Two mini plates are chosen, the last hole in every plate is used to solder the ball housing of type IV Herbst appliance.~2. The two mini plates are placed bilateral at the mandibular symphysis and fixed by at least 3 screws, the surgical wound is sutured.~3. The surgical wound is left for 2 weeks for proper soft tissue healing, in the meantime separation in the arch, band placement on the first premolar and molar bilateral followed by impression for construction of the upper Herbst splint.
Study NCT05440526 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TFBC Group
Description: TFBC Group:~1. The patients will be treated by fixed orthodontic appliance with using series of orthodontic NiTi arch wires for levelling and alignment.~2. Installation of series of orthodontic stainless steel arch wires until 0.0019 x 0.0025 inch for both arches.~3. Installation of the Twin Force Bite Corrector appliance for 4 to 6 months.~4. Using of class ΙΙ intra-oral elastics for both sides for 2 to 3 months.
Study NCT04866316 — intervention group
Intervention type: OTHER
Intervention: There is no active intervention as this is a service evaluation
Description: There is no active intervention as this is a service evaluation
Study NCT03796624 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Micropure 1.2.3.
Description: Implantation of intraocular lens (IOL). Name: MicroPure 1.2.3. It is a monofocal intraocular lens consisting of hydrophobic acrylic material. One IOL per patient will be implanted
Study NCT03796624 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PODEYE
Description: Implantation of intraocular lens (IOL). Name: PODEYE It is a monofocal intraocular lens consisting of hydrophobic acrylic material. The IOL will be implanted in the contralateral eye of the same patient already implanted with Micropure 1.2.3.
Study NCT05129826 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the association between periodontitis and malnutrition status
Description: be determine the association between periodontitis and malnutrition status in older adult.
Study NCT01227681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: G-CSF(granulocyte-colony stimulating factor) is planned injected subcutaneously
Study NCT01227681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: G-CSF(granulocyte-colony stimulating factor) is planned injected subcutaneously
Study NCT01227681 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride (NaCl) 0.9 %
Study NCT04052100 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The standard preoperative measures will consist of a recommendation for physical activity and advice on tobacco smoking cessation and reduction of alcohol intake. In addition, patients who suffer from iron deficient anemia will receive intravenous iron and those at risk of malnutrition (Malnutrition Universal Screening Tool ≥2 (www.bapen.org.uk/pdfs/must/must_full.pdf)) or that require weight control for obesity (IMC≥30) will perform a nutrition intervention by a nutritionist.
Study NCT04052100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation
Description: The experimental group will also carry out a prehabilitation program consisting in:~A. A motivational interview to reinforce the patient's motivation and generate a commitment in relation to the objectives of the program.~B. A physical activity promotion program to increase the number of daily steps of patients, measured by a wristband and a mobile App.~C. A supervised high-intensity exercise training program. D. An individualized nutritional optimization plan with dietary advice and protein supplementation (if necessary). Educational material and motivational messages will be sent through a mobile App.~F. Psychological support through weekly Mindfulness sessions (1.5 hours duration). Educational material and motivational messages will be sent through a mobile App.~E. A smoking cessation program consisting psycho-cognitive therapy combined with pharmacological treatment. Educational material and motivational messages will be sent through a mobile App.
Study NCT01396642 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical Emollient
Description: Neonates in this group will receive topical emollient application with coconut oil twice a day till 28th day of life
Study NCT00401856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone
Description: 50mg oral route
Study NCT00401856 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is identical to eplerenone but the active ingredient is absent
Study NCT01952574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: Administered by study site staff once a month (QM) as a subcutaneous injection
Study NCT01952574 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Erenumab
Description: Administered by study site staff once a month (QM) as a subcutaneous injection
Study NCT01952574 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by study site staff once a month (QM) as a subcutaneous injection
Study NCT01952574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab PFS
Description: Erenumab supplied in a single-use prefilled syringe for self-administration in the CHU substudy
Study NCT01952574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab AI/Pen
Description: Erenumab supplied in a single-use autoinjector/pen for self-administration in the CHU substudy
Study NCT02082613 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lord´s procedure
Study NCT02082613 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sclerotherapy
Study NCT01583387 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 1-Increased water intake regimen
Description: Arm 1-Intervention
Study NCT01583387 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 2-Non-modified water intake regimen
Description: Arm 2-Control
Study NCT03892642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Induction phase:~* once weekly for weeks 1-6,~* once every 2 weeks at week 8, 10, and 12~Maintenance phase:~* Once every week for weeks 1-3~* Once every 2 weeks starting at week 5, until the next BCG treatment
Study NCT03892642 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG
Description: Induction phase (cycle 1):~• Once weekly for weeks 1-6~Maintenance phase (Month 3, 6, and 12):~• Once weekly for 3 weeks
Study NCT00832455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast sodium
Description: Montelukast 4-5 mg for 12 weeks, oral tablet
Study NCT04389164 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tissue-engineered skin grafts of autologous scar dermal scaffolds
Description: 1. scar excision. The thickness of scar tissue in the middle of scar is removed with a roller cutter and the thickness is about 0.01 -- 0.02mm.~2. take autologous skin slices of the patient with an electric skin knife, cut out a small piece of skin, and prepare autologous epidermal basal cell suspension for use;The rest of the skin should be the same size as the wound.~3. the prepared autogenous scar dermal stent was grafted onto the scar resection wound surface, and the prepared autoepidermal basal cells were sprayed between the mesh and on the dermal stent, and autologous skin slices were grafted onto the wound surface and fixed with pressure bandaging;~4. after the operation, the outer dressing should be changed regularly according to the conventional treatment, and the wound surface condition should be observed and recorded according to the experimental scheme.
Study NCT04389164 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue-engineered skin grafts of autologous scar dermal scaffolds
Description: 1. scar excision. The thickness of scar tissue in the middle of scar is removed with a roller cutter and the thickness is about 0.01 -- 0.02mm.~2. take autologous skin slices of the patient with an electric skin knife, cut out a small piece of skin, and prepare autologous epidermal basal cell suspension for use;The rest of the skin should be the same size as the wound.~3. the prepared autogenous scar dermal stent was grafted onto the scar resection wound surface, and the prepared autoepidermal basal cells were sprayed between the mesh and on the dermal stent, and autologous skin slices were grafted onto the wound surface and fixed with pressure bandaging;~4. after the operation, the outer dressing should be changed regularly according to the conventional treatment, and the wound surface condition should be observed and recorded according to the experimental scheme.
Study NCT04369144 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dynamic Scapular Recognition exercise
Description: The intervention group received continual vertical downward correction using a standardized rigid tape. A hypoallergenic tape (Hypafix; BSN Medical GmbH, Hamburg, Germany) was used with 50% to 75% tension. Two rigid tapes were applied; the first one is placed from just superior to the midpoint of the superior border of the scapula to the level of T12 and the second tapes were placed from just superior to the superior angle of the scapula to the level of T12. The level of T12 was used as the end of both taps to increase the lever arm of the applied force and to decrease the incidence of peeling off of the tape. No tape was applied from the lateral angle of the scapula because it might impair the upward rotation of the scapula. Both taps were performed after each session and removed immediately before the next session
Study NCT04369144 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic Scapular Recognition exercise
Description: The intervention group received continual vertical downward correction using a standardized rigid tape. A hypoallergenic tape (Hypafix; BSN Medical GmbH, Hamburg, Germany) was used with 50% to 75% tension. Two rigid tapes were applied; the first one is placed from just superior to the midpoint of the superior border of the scapula to the level of T12 and the second tapes were placed from just superior to the superior angle of the scapula to the level of T12. The level of T12 was used as the end of both taps to increase the lever arm of the applied force and to decrease the incidence of peeling off of the tape. No tape was applied from the lateral angle of the scapula because it might impair the upward rotation of the scapula. Both taps were performed after each session and removed immediately before the next session
Study NCT03192488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine
Description: Cetirizine tablet 10 mg
Study NCT03192488 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Gelatin placebo
Study NCT03192488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxia
Description: Exposure to a 14.3% oxygen environment simulating an altitude of 3,000m/9,000ft
Study NCT03192488 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hypoxia
Description: Exposure to a 14.3% oxygen environment simulating an altitude of 3,000m/9,000ft
Study NCT03328507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI4900
Description: BLI4900 Bowel Preparation
Study NCT03328507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG Control
Description: Polyethylene glycol-based bowel preparation
Study NCT03239249 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IKO-model
Description: A systematic model for drop-out prevention.
Study NCT03239249 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Schools randomized to control group (22) work as previously with school dropout
Study NCT00937976 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Periodontal Scaling and Root Planing
Description: Participants will take antibiotics prior to dental treatment. Periodontal treatment or a deep cleaning (with local anesthesia or numbing) will be performed to remove plaque and tartar around the teeth and gums. A small amount of antibiotics (minocycline) will be placed around the gums to help fight bacteria and inflammation.
Study NCT02178657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cell intra-arterial injection
Study NCT01788631 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regadenoson
Description: Regadenoson is an A2AR agonist that is a coronary vasodilator. It is chemically described as adenosine, 2-\[4-\[(methylamino)carbonyl\]-1H-pyrazol-1-yl\]-, monohydrate. Its molecular formula is C15H18N8O5. Regadenoson has an FDA indication for use in radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress. It has lower affinity for non-A2A adenosine receptor subtypes thought to be associated with some of the adverse effects associated with non-selective adenosine receptor agonists, which increase extracellular adenosine by blocking its uptake into cells. The maximal plasma concentration of regadenoson is achieved within 1 to 4 minutes after injection and parallels the onset of the pharmacodynamic response. Its half-life is approximately 2 to 4 minutes.
Study NCT01788631 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This study uses 0.9% Normal Saline (NS) as placebo. This is a sterile sodium chloride solution usually used to replenish fluids and electrolytes. It contains no additives, and is a standard solution used as placebo in clinical trials where the study drug is administration intravenously. NS will be prepared by investigational pharmacy.
Study NCT01842360 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subjects will receive daily dose of placebo during 12 months
Study NCT01842360 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MV130
Description: The subjects will receive daily dose of MV130 during 12 months
Study NCT04129489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Synthetic Cannabidiol, dissolved in pharmaceutical grade olive oil at a concentration of 5% will be administered orally
Study NCT03520777 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Art Intervention
Description: Type of artist intervention will be determined by the subject and the assigned artist.
Study NCT02182843 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cellentra VCBM
Description: Cellentra™ VCBM is an allogenic bone graft containing naturally occurring viable donor cells intended for homologous use in the repair, replacement, reconstruction or supplementation of the recipient's tissue in musculoskeletal defects.
Study NCT00938769 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Self-Efficacy Training for Caregivers
Description: The Enhanced Caregiver Training intervention will be delivered to informal caregivers of cancer patients before hospital discharge who are randomly selected to receive this intervention. Subjects in the treatment group will receive an individualized experiential caregiver training in strategies for managing patient's symptoms and in the use of pleasant imagery and muscle relaxation to manage stress.~2-hour in-person instruction of home care issues for caregivers of patients with cancer.